Compare CTNT & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTNT | IMMP |
|---|---|---|
| Founded | 2016 | 1987 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.5M | 58.2M |
| IPO Year | 2023 | 2012 |
| Metric | CTNT | IMMP |
|---|---|---|
| Price | $0.16 | $0.58 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 6.4M | ★ 19.6M |
| Earning Date | 05-04-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.74 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,288,536.00 | N/A |
| Revenue This Year | $42.49 | $417.85 |
| Revenue Next Year | $22.22 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 182.69 | N/A |
| 52 Week Low | $0.14 | $0.29 |
| 52 Week High | $2.12 | $3.53 |
| Indicator | CTNT | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 19.13 | 37.74 |
| Support Level | N/A | N/A |
| Resistance Level | $1.58 | $1.75 |
| Average True Range (ATR) | 0.20 | 0.07 |
| MACD | -0.12 | 0.11 |
| Stochastic Oscillator | 1.27 | 38.24 |
Cheetah Net Supply Chain Service Inc is a provider of logistics and warehousing services, historically in connection with the sale of parallel-import vehicles sourced in the U.S. to be sold in the PRC market, and more recently for the transportation of other goods between the U.S. and the PRC. Parallel-import vehicles in the PRC refer to automobiles purchased directly from overseas markets and imported for sale outside of the brand manufacturer's official distribution networks. The company operates as single report segment. The company operates in the USA and overseas.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.